



JPW

PATENT  
Attorney Docket No.: CIT1510-5

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Lyapina et al. Art Unit: Not Yet Assigned  
Application No.: 10/723,475 Examiner: Not Yet Assigned  
Filing Date: November 25, 2003 Confirmation No.: Not Yet Assigned  
Title: REGULATION OF TARGET PROTEIN ACTIVITY THROUGH  
MODIFIER PROTEINS


MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.97, references relating to the above-identified application are listed on the attached Form PTO-1449. Copies of the references will be found in prior application, U.S. Serial No. 10/046,961, filed January 14, 2002, which is relied upon for an earlier filing date under 35 U.S.C. § 120. A copy of the Supplementary Partial European Search Report issued for a counterpart European application also is enclosed.

It is respectfully requested that the references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, August 6, 2004, in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	August 6, 2004 (Date)

In re Application of:  
Lyapina et al.  
Application No.: 10/723,475  
Filed: November 25, 2003  
Page 2



PATENT  
Attorney Docket No.: CIT1510-5

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: August 6, 2004

A handwritten signature in cursive script that reads "Lisa A. Haile". The signature is written over a horizontal line.

Lisa A. Haile, J.D., Ph.D.  
Registration No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
USPTO CUSTOMER NO. 28213

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	Docket No.: CIT1510-5	Application No.: 10/723,475
	Applicants: Lyapina et al.	Confirmation No.: Not Yet Assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Filing Date: November 25, 2003	Group Art Unit: Not Yet Assigned

### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AI	5,976,796 A	11/02/1999	Szalay et al.	435	6	12/23/1996

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AJ	1 130 029 A1	09/05/2001	EP	C07K	14/47	
	AK	00/29436 A1	05/25/2000	WO	C07K	14/47	
	AL	00/79267 A2	12/28/2000	WO	G01N	33/48	

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AM	Bech-Otschir et al., "COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system", <i>EMBO J.</i> , 2001 Apr., 20(7):1630-9
	AN	Deshais, "SCF and Cullin/Ring H2-based ubiquitin ligases", <i>Annu Rev Cell Dev Biol.</i> 1999, 15:435-67
	AO	Eytan et al., "Ubiquitin C-terminal hydrolase activity associated with the 26 S protease complex", <i>J Biol Chem.</i> , 1993 March, 268(7):4668-74
	AP	Löwe et al., "Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution", <i>Science.</i> , 1995 April, 268(5210):533-9
	AQ	Reiss et al., "Specificity of binding of NH2-terminal residue of proteins to ubiquitin-protein ligase. Use of amino acid derivatives to characterize specific binding sites", <i>J Biol Chem.</i> , 1988 Feb., 263(6):2693-8
	AR	Tomoda et al., "Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1", <i>Nature.</i> , 1999 March, 398(6723):160-5

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

Gray Cary/GT6409997.1  
104662-142



PATENT  
Attorney Docket No.: CIT1510-5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Lyapina et al.	Art Unit:	Not Yet Assigned
Application No.:	10/723,475	Examiner:	Not Yet Assigned
Filing Date:	November 25, 2003	Confirmation No.:	Not Yet Assigned
Title:	REGULATION OF TARGET PROTEIN ACTIVITY THROUGH MODIFIER PROTEINS		


MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith for the above-identified application please find:

1. Information Disclosure Statement (2 pgs.);
2. Form PTO-1449 (1 pg. in duplicate);
3. Supplementary Partial European Search Report (6 pgs.) and
4. Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, August 6, 2004, in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	August 6, 2004 (Date)

In re Application of:  
Lyapina et al.  
Application No.: 10/723,475  
Filed: November 25, 2003  
Page 2



PATENT  
Attorney Docket No.: CIT1510-5

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355. A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Date: August 6, 2004

A handwritten signature in cursive script, reading "Lisa A. Haile".

\_\_\_\_\_  
Lisa A. Haile, J.D., Ph.D.  
Registration No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
USPTO CUSTOMER NO. 28213